Role of HPBCD in development of Pfizer’s novel COVID-19 oral antiviral treatment candidate
Pfizer’s breakthrough drug candidate PF-07321332 used in combination with ritonavir was poven to successfully reduce the risk of hospitalization and
Tag: Covid-19
METHYL-CYCLODEXTRIN FOR USE IN TREATING ENVELOPED VIRUS INFECTIONS SUCH AS SARS-CoV-2
The patent application (1) with priority date of 09. March 2020 claims that methyl bCD preferably with DS 0.7 (Crysmeb)
Memorial Sloan Kettering Cancer Center: Potential treatment of COVID-19 using inhalable camostat/nafamostat formulated with HPBCD or SBECD
Memorial Sloan Kettering Cancer Center (MSKCC) has filed a patent application on an inhalational therapeutic composition of camostat solubilized by
Updates on development of oral remdesivir formulations
Jubilant Pharmova subsidiary Jubilant Pharma has concluded safety and pharmacokinetic/absorption studies of a new oral formulation of remdesivir in animals
Harvard scientists discover the prophylactic effect of SBECD solubilized amodiaquine against SARS-CoV2 infection
Amodiaquine is a commonly used medicament for the treatment of malarial infections. It is a 4-aminoquinoline compound similar to chloroquine
Trends in the development of remdesivir based inventions against COVID-19 and other disorders: A patent review
The development of remdesivir has been a breakthrough for COVID-19 treatment. It has been approved in about 50 countries since
Safety of inhaled HPBCD-formulated ivermectin as a repurposed direct drug for treatment of COVID-19: A preclinical tolerance study
SARS-CoV-2 replication in cell cultures has been shown to be inhibited by ivermectin. However, ivermectin’s low aqueous solubility and bioavailability hinders
Intraoral/intranasal niclosamide/HPBCD formulation for treatment of COVID-19
A recently published patent of Union Therapeutics, Denmark (US11045434) (granted extremely rapidly by USPTO within 8 months from filing date)
Efficacy and safety of remdesivir in COVID-19 caused by SARS-CoV-2: a systematic review and meta-analysis
The aim of the study was evaluation of remdesivir, an RNA polymerase inhibitor, for effectiveness in adults with COVID-19. 52
Recent reviews on cyclodextrins against SARS-CoV-2
Recent reviews emphasized the role of membrane lipids in the infectivity mechanism of SARS-COV-2. Cholesterol-rich parts of cell membranes serve